Gilead, Merck put aside rivalry to challenge GlaxoSmithKline for long-acting HIV meds
Joan Butterton was sitting 30,000 feet above the Atlantic, flying to a conference in Europe, when the Merck scientist seated next to her started gushing about the HIV molecule the big pharma had just licensed from a small Japanese company. It was so potent in monkeys, the scientist said, that they couldn’t figure out what the lowest effective dose was and it stayed in the animals for an incredibly long time, far longer than the approved drugs HIV patients took daily.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 125,100+ biopharma pros reading Endpoints daily — and it's free.